Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Vieth

Showing results (351-360 of 482) with videos related to

Pageof 49
Sort By:
Human Pathology|July 20, 2021
Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodesAndrianos Tsekrekos, Michael Vieth, Nelson Ndegwa, et al.
Annals of the New York Academy of Sciences|October 1, 2014
Adenocarcinoma at the gastroesophageal junctionSahar Al-Haddad, Andrew C Chang, Gert De Hertogh, et al.
Clinical and Vaccine Immunology : CVI|September 6, 2013
A novel line immunoassay based on recombinant virulence factors enables highly specific and sensitive serologic diagnosis of Helicobacter pylori infectionLuca Formichella, Laura Romberg, Christian Bolz, et al.
Cancer Prevention Research (Philadelphia, Pa.)|November 4, 2016
Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal AdenocarcinomaRaphael Schellnegger, Anne Quante, Susanne Rospleszcz, et al.
Zeitschrift Fur Gastroenterologie|June 7, 2022
[Position paper on reporting of intestinal ultrasound findings in patients with inflammatory bowel disease]Torsten Kucharzik, Raja Atreya, Oliver Bachmann, et al.
Helicobacter|November 9, 2011
Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infectionStephan Miehlke, Susanne Krasz, Wulf Schneider-Brachert, et al.
Inflammatory Bowel Diseases|March 24, 2010
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitisTilo Andus, Andreas Kocjan, Moritz Müser, et al.
Cell Reports|September 16, 2020
Toll-like Receptor 5 Activation by the CagY Repeat Domains of Helicobacter pyloriNicole Tegtmeyer, Matthias Neddermann, Judith Lind, et al.
Journal of Crohn'S & Colitis|July 6, 2022
PU.1-driven Th9 Cells Promote Colorectal Cancer in Experimental Colitis Models Through Il-6 Effects in Intestinal Epithelial CellsKatharina Gerlach, Vanessa Popp, Stefan Wirtz, et al.
Histopathology|April 19, 2018
The outlet patch: gastric heterotopia of the colorectum and anusAbul A S R Mannan, Michael Vieth, Armen Khararjian, et al.
Pageof 49

Showing results (351-360 of 482) with videos related to

Sort By:
Pageof 49
Human Pathology|July 20, 2021
Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodesAndrianos Tsekrekos, Michael Vieth, Nelson Ndegwa, et al.
Annals of the New York Academy of Sciences|October 1, 2014
Adenocarcinoma at the gastroesophageal junctionSahar Al-Haddad, Andrew C Chang, Gert De Hertogh, et al.
Clinical and Vaccine Immunology : CVI|September 6, 2013
A novel line immunoassay based on recombinant virulence factors enables highly specific and sensitive serologic diagnosis of Helicobacter pylori infectionLuca Formichella, Laura Romberg, Christian Bolz, et al.
Cancer Prevention Research (Philadelphia, Pa.)|November 4, 2016
Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal AdenocarcinomaRaphael Schellnegger, Anne Quante, Susanne Rospleszcz, et al.
Zeitschrift Fur Gastroenterologie|June 7, 2022
[Position paper on reporting of intestinal ultrasound findings in patients with inflammatory bowel disease]Torsten Kucharzik, Raja Atreya, Oliver Bachmann, et al.
Helicobacter|November 9, 2011
Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infectionStephan Miehlke, Susanne Krasz, Wulf Schneider-Brachert, et al.
Inflammatory Bowel Diseases|March 24, 2010
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitisTilo Andus, Andreas Kocjan, Moritz Müser, et al.
Cell Reports|September 16, 2020
Toll-like Receptor 5 Activation by the CagY Repeat Domains of Helicobacter pyloriNicole Tegtmeyer, Matthias Neddermann, Judith Lind, et al.
Journal of Crohn'S & Colitis|July 6, 2022
PU.1-driven Th9 Cells Promote Colorectal Cancer in Experimental Colitis Models Through Il-6 Effects in Intestinal Epithelial CellsKatharina Gerlach, Vanessa Popp, Stefan Wirtz, et al.
Histopathology|April 19, 2018
The outlet patch: gastric heterotopia of the colorectum and anusAbul A S R Mannan, Michael Vieth, Armen Khararjian, et al.
Pageof 49